Welcome, Guest
Username: Password: Remember me
Cytori´s Platform applications
  • Page:
  • 1

TOPIC: Renal patent

Renal patent 29 Mar 2013 10:10 #353

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3301
  • Thank you received: 1110
The market yawned again after yesterdays announcement and yes- I agree it possibly could have something to do with investors and that market anticipating a secondary again (and NOT a partner deal, although this announcement will only improve chances on that score)

Renal is one of the apps which should be top or near the top of any investors wish-list for development by Cytori WITH a partner- clearly Cytori does not have the financial resources to do something by themselves.

I wrote an article about it on the application page- Inflammatory app- Acute Renal Failure so you can re-visit this, but lets have a look at the announcement again-

The '229 patent complements Cytori's previously issued European Patent No. 1 778 834 (the '834 patent) directed to the treatment of renal disorders. Similar to the '229 US patent, the '834 European patent covers treatment of a broad range of renal disorders, including AKD and CKD. The '834 patent is effective in the United Kingdom, Germany, France, Netherlands, Spain, Belgium, Sweden, and select other European countries. Cytori now has 60 issued patents and more than 75 active patent applications worldwide.

"The renal patents are an important addition to our growing portfolio of ADRC patents," said Chris Calhoun, Chief Executive Officer of Cytori. "CKD is an important co-morbidity of cardiovascular disease, Cytori's core focus. Our platform technology and recent European approval of Intravase® for intravascular delivery allows us to explore related indications without compromising our focus on the core indications. Potentially, we would partner this indication to expedite bringing this therapy to market."


Remember- in August 2009 an analyst already asked Hedrick in the Call how the first treated patient was doing- answer at the time- too early to tell and NOTHING has been heard about developments since than. As you know- that makes me suspicious. Renal is an EXCELLENT application candidate for fat cells in view of the anti-inflammatory and blood flow properties of the cells.

As you can see- this is NOT a Celution patent - THIS IS A FAT CELLS PATENT a monopoly position on ACUTE and CHRONIC kidney disease. !!!

Actually I do expect a partner deal soon on this indication- the opportunity is simply gigantic, especially if it works and I think some folks know this already. :woohoo:



Chronic is THE biggest market of them all- so nothing to yawn really... :really:
Attachments:
The following user(s) said Thank You: Joncon63, joeycav11

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Renal patent 29 Mar 2013 11:47 #354

  • joeycav11
  • joeycav11's Avatar
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 130
  • Thank you received: 41
Thanks for the elaboration Fas. I think the deals are ready to come through in the sector. I don't know but this is a pretty small community (The US cell therapy market) My thinking is that these companies like ATHX ACTC CYTX among others are holding out for some big dollars. When and if a good partnership is announced by anyone the sector takes off.
ACTC might be showing efficacy in the next month in phase 2 for Macular degeneration. If that happens consensus is a big deal very quickly for Europe. Second ATHX looks close to a deal and maybe we are to.

Please Log in or Create an account to join the conversation.

Renal patent 29 Mar 2013 15:22 #355

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2771
  • Thank you received: 199
Ha !
Was looking at the same graphic myself today Fas... from a old (June/2008) Zacks report.

The estimated sales revenue at the time of $4K/procedure seems light given the potential savings to a healthcare system...I think, SHOULD Cytori ever garner a partner here, they should be able to still get that amount. Charging $8K for the kit and a 50/50 split with a partner.

For us, if a partner were found the upfront cash would be the immediate benefit as the road to market and reimbursement would likely be 5 years away or so following such a deal.

Please Log in or Create an account to join the conversation.

Renal patent 30 Mar 2013 10:46 #356

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 380
  • Thank you received: 196
Hedge, Fas, this indication is huge. Here are two interesting articles about the disease.

usatoday30.usatoday.com/news/health/2009-08-23-dialysis_N.htm
ndt.oxfordjournals.org/content/23/6/1982.full

The average ANNUAL cost in the UK for dialysis is approx. GBP 25,000. An $8,000 price tag for a treatment that can improve patients quality of life while also contributing to a significant reduction in the cost of care should meet the most miserly requirements demanded by the UK "pay for performance" criteria. These costs do not include the additional hospital costs that arise from complications arising from renal failure...... intensive care etc.

One interesting observation in the UK study related to an additional cost of care..... "It should also be recognized that a major cost driver for modality costs was erythropoietin for the treatment of anaemia." I assume that if the frequency of dialysis was reduced or no longer needed then there would be a commensurate decrease in very expensive drugs supplied by the likes of Amgen & JNJ.

The benefit to the National Health Care Systems globally is beyond huge. This indication is a black hole in terms of funding. We are fast running up against limits that conventional treatment CANNOT cover. Assuming that CYTX's technology platform acts as well as we hope/believe then this will not only be a godsend for patients but also for taxpayers worldwide. :woohoo:

When reading about this indication and contemplating the effect that regenerative medicine can have on it one begins to appreciate Schumpeter's concept of Creative Destruction ................ I have been very pissed of with the delay in the Celution ADRC platform's commercial development.......... I wonder though how shareholders in AMGN, JNJ, Fresenius and DaVita will feel about it when we succeed?????.

My frustration level with past delays and failures is huge. I however cannot begin to express my outrage that huge amounts of tax dollars are wasted instead of being used in a no brainer trial that would benefit society beyond belief. :bash:

CYTX management is absolutely right to demand top dollar to share this technology. :yep:

Please Log in or Create an account to join the conversation.

Renal patent 30 Mar 2013 12:26 #357

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3301
  • Thank you received: 1110

When reading about this indication and contemplating the effect that regenerative medicine can have on it one begins to appreciate Schumpeter's concept of Creative Destruction ................ I have been very pissed of with the delay in the Celution ADRC platform's commercial development.......... I wonder though how shareholders in AMGN, JNJ, Fresenius and DaVita will feel about it when we succeed?????.


Your reference to Schumpeter reminds me of the early days of following Cytori- 2004/5 or so. Thats when I wrote similar references to the technology too. Mind you, we are not the only ones. One of the silent readers of the site is a German professor specialized in Schumpeter theories and he wrote me a few months ago, that he is the reviewer of a doctor paper on the developments in the health care system and a chapter is also devoted to Cytori.
Of course- he is a shareholder of Cytori and I "discovered/found" him, while a found the first chapters on the web of a scientific paper he started writing in 2008 I believe- of course its about Cytori technology and Schumpeter. :winky:
The following user(s) said Thank You: kekzy

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Renal patent 31 Mar 2013 21:26 #358

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2771
  • Thank you received: 199
Oh I agree rongside...incredible potential.

Not only help the renal function part but bank extra cells for wound treatment that these patients often suffer from with chronic disease.
It would be interesting if insurance would pay for banking under preventative medicine in such a case. Hmmm...maybe too much fore-sight on my part.

Of course...with a good response, we would hopefully limit such events.

For now though...it sits on the unfulfilled potential self with the rest of the indications. :cry:

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.709 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites